Follow the news and you know: Scientists are more than just chipping away at cancer. They are kicking down the barricades. Cell therapies are, at long last, delivering lasting remissions in a few indications. Small molecules and antibodies with new mechanisms of action – sometimes in clever combination – are raising the bar, making cancer more of a chronic and tolerable disease. Underlying information on gene mutations, dysregulated protein networks and the tumor microenvironment provide a vivid glimpse of malignancy at the molecular level, and a wellspring for new therapeutic ideas. Much of this progress is occurring here in Massachusetts. Hear from the leaders in Big Pharma, venture capital, public biotech companies, and emerging startups at The Boston Cancer Summit, March 7. All proceeds go to the Mt. Everest Climb to Fight Cancer campaign at Fred Hutchinson Cancer Research Center.